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Summary. Background: A disintegrin and metalloproteinase
with a thrombospondin type 1 motif, member 13 (ADAMTS-
13) may inﬂuence von Willebrand factor (VWF) levels and
consequently the risk ofmyocardial infarction (MI).Moreover,
ADAMTS-13 inﬂuences hemostatic plug formation in mouse
models. We therefore studied their associations in the Glasgow
MI Study (GLAMIS). Methods and results: We measured
ADAMTS-13 and VWF antigen levels by ELISAs in stored
plasma from a case–control study of 466MI cases and 484 age-
and sex-matched controls from the same north Glasgow
population. There was no correlation between ADAMTS-13
and VWF levels in cases or controls. ADAMTS-13 levels
correlated positively with serum cholesterol and triglycerides
and body mass index, and negatively with high-density
lipoprotein-cholesterol. VWF levels correlated with age, ﬁbrin-
ogenandC-reactive protein. Inmultivariable analyses including
risk factors, VWF correlated positively with risk of MI, and
ADAMTS-13 correlated negatively with risk of MI. These
associations were independent of each other. The association of
ADAMTS-13 with risk of MI was observed only in multivar-
iable analysis. Conclusions: VWF and ADAMTS-13 levels
were not associated in this study, and showed associations with
MI risk in opposite directions but of similar strength. The
association of ADAMTS-13 with MI is inﬂuenced by lipid
levels, and consequently requires further investigation.
Keywords: ADAMTS-13, Glasgow Myocardial Infarction
Study, myocardial infarction, VWF.
Introduction
Von Willebrand factor (VWF) plays an important role in
hemostasis and thrombosis, both as a cofactor in platelet
adhesion and aggregation and as the circulating carrier
protein for coagulation factor VIII [1]. Meta-analyses of
prospective studies have suggested that increasing circulating
VWF levels are associated with increased risk of coronary
heart disease (CHD) [2,3], although in the most recently
reported meta-analysis this association was relatively weak [3].
The molecular weight/multimeric composition of VWF is a
key determinant of its platelet-tethering function. This is
modulated by a disintegrin and metalloproteinase with a
thrombospondin type 1 motif, member 13 (ADAMTS-13).
ADAMTS-13 cleaves the VWF A2 domain, reducing its
molecular weight and consequently also its platelet-tethering
function [4–8]. Deﬁciency of ADAMTS-13 promotes VWF-
induced platelet aggregation, which can result in thrombotic
thrombocytopenic purpura [4]. In mouse models of throm-
bosis, ADAMTS-13 downregulates both platelet adhesion to
the exposed subendothelial matrix and thrombus formation in
injured arterioles [9]. It has therefore been suggested that
circulating levels of ADAMTS-13 may inﬂuence circulating
levels of VWF and/or its function, and it may therefore
inﬂuence risk of thrombotic events such as myocardial
infarction (MI) in the general population.
We have studied this hypothesis in a case–control study
of ﬁrst episode of MI, the Glasgow Myocardial Infarction
Study (GLAMIS) [10]. We studied the distributions and
correlations of VWF and ADAMTS-13 with CHD risk
factors, and with each other. Thereafter, we studied the
associations of VWF and ADAMTS-13 with MI, following
adjustment for risk factors – including high-density lipopro-
tein (HDL)-cholesterol, ﬁbrinogen and C-reactive protein
(CRP) [10] – and each other.
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Subjects and methods
GLAMIS [10] is a case–control study wherein cases ofMI were
derived from the international MONICA study [11] register in
north Glasgow [12] in 1994–1995. Survivors on the register
were recruited between 3 and 9 months after their MI event.
We have previously studied VWF serially between 1 and
6 months following MI values. These data showed that VWF
levels were stable and lower than on admission [13]. Conse-
quently, the sampling of plasmas between 3 and 9 months post-
MI event in this study should not be inﬂuenced by the acute-
phase protein response to MI. The time lag between the event
and recruitment ensured that acute-phase protein reactions in
acute MI had settled. Controls were selected from a random
sample of the same north Glasgow population, obtained from
general practice registers. Controls were frequency-matched for
sex (726men and 269 women) and age (within 1 year), and had
no self-reported history, or electrocardiogram evidence, of MI.
In all but 2.5% of controls, electrocardiography veriﬁed the
absence of evidence of MI. Written informed consent was
obtained from all participants, and the study was approved by
the local Research Ethics Committee.
Participants completed a general health questionnaire (taken
after the MI in the case of patients), which included questions
on age (range 25–64 years), sex, diabetes status (yes/no),
smoking status (current smoker/ex-smoker/never smoked cig-
arettes), and medication used, which related to the time after
the MI in the case of patients. Subjects attended at a clinic
where weight, height and blood pressure were recorded. Body
mass index (BMI) was calculated as weight divided by the
square of height. A forearm venous sample was taken after a
full overnight fast. Lipid assays were measured as previously
described [9]. The assays of inﬂammatory and hemostatic
variables used blood anticoagulated with dipotassium ethylen-
ediaminetetraacetic acid (EDTA; 1.5 mg mL)1), centrifuged at
2000 g for 10 min at room temperature within 2 h of sampling,
and aliquots were stored at )70C. Fibrinogen was assayed in
citrated plasma using the von Clauss method on an MDA-180
analyzer (Organon Teknika, Cambridge, UK) and an ultra-
sensitive assay for CRP was performed in citrated plasma on a
nephelometer (Dade-Behring, Marburg, Germany), as previ-
ously described [10]. VWF antigen was assayed in citrated
plasma by an in-house ELISA, using reagents from DAKO
(Copenhagen, Denmark); the interassay coefﬁcient of variance
(CV) was 3.3%. ADAMTS-13 was assayed in dipotassium
EDTA plasma using an in-house ELISA as previously
described [14] with an interassay CV of <5%.
Statistical analysis
VWF, ADAMTS-13, continuous major cardiovascular risk
factors (age, blood pressure, serum lipids, BMI), ﬁbrinogen and
CRP were compared between MI cases and controls using
general linear models, which adjusted for age and sex. Skewed
continuous variables were transformed; VWF and ADAMTS-
13 were approximately normally distributed after a log and a
square root transformation, respectively. Binary major cardio-
vascular risk factors (whether the subject was: male; had
diabetes; had ever smoked; was currently takingmedication for
high blood pressure; or was currently taking medication for
high cholesterol) were compared between MI cases and
controls using logistic regression models, which adjusted for
age and sex. The age- and sex-adjusted relationships between
both VWF and ADAMTS-13 and each of the continuous
potential confounding variables, taken one at a time, were
estimated for controls from general linear models, after
transforming each of the dependent variables to approximate
normality. Age- and sex-adjusted correlations between VWF
and ADAMTS-13 were also estimated after these transforma-
tions. Logistic regression models were used to obtain odds
ratios (ORs) for MI by equal thirds of the values for VWF and
ADAMTS-13 (in both patients and controls) and for a
continuous 1 standard deviation (SD) increase in each variable
amongst the controls. Three sets of adjustments were used in
evaluating the association between VWF and the risk of MI,
each with and without further adjustment for ADAMTS-13:
age and sex; all continuous and binary major cardiovascular
risk factors; and additionally ﬁbrinogen and CRP. Similar
adjustments were made for ADAMTS-13, with and without
adjustment for VWF. Interactions were tested by adding terms
to the relevant statistical models [15].
Results
ADAMTS-13 or VWF data were available for 950 plasma
samples. Due to incomplete residual aliquots, VWF was
measured in 875 (88%) and ADAMTS-13 in 919 (94%) of the
995 participants in GLAMIS. Cases had signiﬁcantly higher
average values for triglycerides, BMI, ﬁbrinogen, CRP and
VWF than controls, but lower values for blood pressure and
HDL-cholesterol (Table 1). Cases were also more likely than
controls to have ever smoked (89% vs. 74%), to have diabetes
(12% vs. 2%), and to be taking medication for high blood
pressure (39% vs. 17%) or for high cholesterol (28% vs. 1%)
(data not shown). As anticipated by design, there were no
signiﬁcant differences in either age or sex between cases and
controls. There were also no signiﬁcant differences in levels of
total cholesterol or ADAMTS-13.
In Table 2, plasma levels of ADAMTS-13 and VWF in
control subjects (for whom both values were available) are
shown according to the different binary variables. In controls
therewas no signiﬁcant age-/sex-adjusted difference (P > 0.05)
in mean VWF by sex, ever-smoking status, diabetes status, or
use ofmedication for highbloodpressure or for high cholesterol
(Table 2). ADAMTS-13 was higher in those taking compared
with those not takingmedication for high blood pressure.None
of the other comparisons of ADAMTS-13 levels showed any
differences amongst the different groups analyzed.
Age-/sex-adjusted correlations between transformed values
of ADAMTS-13 and VWFwere )0.01 (P = 0.81) for controls
and )0.06 (P = 0.23) for cases (data not shown). From
analysis of control individuals for whom both ADAMTS-13
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and VWF values were available (n = 484), there were positive
relationships between VWF and age and ﬁbrinogen (Table 3).
Similarly, there were strong positive correlations between
ADAMTS-13 and total cholesterol, triglycerides and BMI
(Table 3). There was also a notable negative correlation
between ADAMTS-13 and HDL-cholesterol.
The OR of MI increased with increasing thirds of VWF.
After adjustment for age and sex, those in the highest third
had about three times the risk of those in the ﬁrst (Table 4).
Assuming a log-linear decline is an acceptable model, an
increase of 1 SD (60.3 IU dL)1) of VWF was estimated to
increase the odds of MI by 51%, after correction for age and
sex (Table 4, Adjusted I). Adjustment for ADAMTS-13 had
little effect on the ORs for VWF. Adjustment for established
cardiovascular disease risk factors moderately reduced the OR
for VWF (Table 4, Adjusted II and III). There was no
evidence of a difference in the OR for MI over increasing
thirds of ADAMTS-13, after adjustment for age and sex
(Table 4, Adjusted I). However, after adjustment for major
cardiovascular disease risk factors, there was a clear inverse
relationship between ADAMTS-13 and MI (Table 4, Adjus-
ted II): those in the highest third had about 54% of the risk of
those in the ﬁrst third, whilst an increase of 1 SD (32.6%) in
ADAMTS-13 was estimated to lead to a 27% reduction in the
odds of MI. The OR for an increase of 1 SD in ADAMTS-13
changed from 1.01 to 0.72 after adjusting for a host of other
potential confounding variables on top of age and sex.
However, no single variable explained the majority of this
decrease; adjustment for HDL-cholesterol caused the largest
change, to 0.91. Adjustment for all the lipid variables (total
cholesterol and HDL-cholesterol, triglycerides and medication
for high cholesterol), as well as age and sex, resulted in an OR
Table 2 Plasma levels of ADAMTS-13 and von Willebrand factor (VWF) in controls amongst the diﬀerent binary variables examined [i.e. according to
sex, smoking, diabetes, and the taking of medication for high blood pressure (BP) or high cholesterol]. P-values after transformations as in Table 1
Yes No









Male? ADAMTS-13 296 111 32.5 107 89.3 126 106 114 34.6 106 93.8 120 0.27
VWF 296 165 62.1 156 121 198 106 160 54.9 152 120 200 0.16
Ever smoked? ADAMTS-13 302 110 32.5 106 88.9 125 98 118 34.3 108 96.0 129 0.11
VWF 302 166 61.4 157 119 201 98 157 56.6 144.5 122 189 0.60
Diabetes? ADAMTS-13 7 126 30.8 117 100 145 393 112 33.1 106 90.8 126 0.20
VWF 7 192 66.3 195 133 261 393 163 60.2 154 121 197 0.32
High BP medication?
ADAMTS13
66 123 40.5 112 98.4 140 334 110 31.0 105.2 90.3 125 0.0009
VWF 66 174 65.6 175 130 207 334 161 59.1 152 120 196 0.44
High cholesterol
medication? ADAMTS-13
5 124 32.0 127 102 129 395 112 33.1 106 90.8 126 0.37
VWF 5 212 95.7 176 175 198 395 163 59.7 154 120 197 0.15
Table 1 Summary statistics for ADAMTS-13, von Willebrand factor (VWF) and continuous coronary risk factors
Controls (n = 484) Cases (n = 466)
n Mean SD Median 1st Quartile 3rd Quartile n Mean SD Median 1st Quartile 3rd Quartile P-value*
Age (years) 484 55.1 7.45 57 50 61 466 54.9 7.46 57 51 61 0.76
Systolic BP
(mmHg)
484 130 19.9 130 116 144 465 123 21.8 121 105 137 <0.0001
Diastolic BP
(mmHg)
484 82.8 11.1 83 75 90 465 78.4 12.8 77 69 87 <0.0001
Total cholesterol
(mmol L)1)
478 5.76 1.16 5.7 4.9 6.5 463 5.80 1.16 5.7 4.9 6.5 0.55
HDL-cholesterol
(mmol L)1)
477 1.35 0.42 1.3 1.0 1.6 463 1.12 0.31 1.1 0.9 1.3 <0.0001
Triglycerides
(mmol L)1)
478 2.10 6.98 1.5 1.0 2.1 463 2.21 1.38 1.9 1.4 2.6 <0.0001
BMI (kg m)2) 484 26. 9 4.62 26 23 30 463 27.9 4.80 27 24 30 0.0003
Fibrinogen (g L)1) 378 3.12 0.67 3.0 2.7 3.5 381 3.44 0.75 3.4 2.9 3.9 <0.0001
CRP (mg L)1) 370 4.17 8.56 1.8 0.8 4.2 385 5.26 6.94 2.9 1.3 6.3 <0.0001
ADAMTS-13 (%) 472 112.6 32.6 106 92 127 447 111 35.9 105 88 125 0.36
VWF (IU dL)1) 414 164 60.3 154 121 199 461 186 68.1 178 141 219 <0.0001
BP, blood pressure. *Test of equality of means, cases vs. controls, after adjustment for age and sex and log transformation for high-density
lipoprotein (HDL)-cholesterol, triglycerides, body mass index (BMI), ﬁbrinogen, C-reactive protein (CRP) and VWF and square root transfor-
mation for ADAMTS-13. Age was adjusted for sex.
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[95% conﬁdence interval (95% CI)] of 0.83 (0.70–0.99; results
not shown). Further adjustment for ﬁbrinogen and CRP (full
adjustment; Table 4, Adjusted III) did not materially alter the
effect of ADAMTS-13. Adjustment of VWF for ADAMTS-
13 had no appreciable effect. There was no interaction
between ADAMTS-13 and VWF in predicting MI for any of
the three adjustment sets, for analyses by thirds or as
continuous variables (P ‡ 0.19).
WhenADAMTS-13 andVWFwere varied together, theOR
(95%CI) comparing those in the highest third of VWF and the
lowest third of ADAMTS-13 with those in the lowest third of
VWF and the highest third of ADAMTS-13, after full
adjustment, was 4.70 (1.76–12.6). This OR is very similar to
the OR of 4.57 that was obtained by multiplication of the fully
adjusted ORs contrasting the extreme thirds when ADAMTS-
13 and VWF were analyzed independently of the other,
restricting analysis to subjects with data on both variables. This
underlines the independence of their effects on MI.
Discussion
This study suggests that both ADAMTS-13 and VWF antigen
are risk factors for a major non-fatal coronary event (MI), with
effects that are in opposite directions, and are clearly indepen-
dent of each other. VWF has effects that are largely unaffected
by other cardiovascular disease risk factors, unlike ADAMTS-
13, which appears to have effects that are masked by the
coexistence of other risk factors. After adjustment for the
largest set of cardiovascular risk factors considered here, an
additional 1 SD of VWF (about 60 IU dL)1) is expected to
raise the risk ofMI by about 35%, similar to the amount (27%)
by which the risk is lowered after increasing ADAMTS-13 by 1
SD. The association of VWF antigen with MI in the current
case–control study is consistent with a recent meta-analysis of
prospective studies of CHD [3].
Our ﬁnding of a lack of association between plasma levels of
VWF and ADAMTS-13 is in agreement with another recent
case–control study of similar size [14]; hence, it appears unlikely
that ADAMTS-13 appreciably affects VWF antigen levels
across the population range. A previous study reported an
Table 4 Odds ratios (95% conﬁdence intervals) for risk of myocardial infarction for ADAMTS-13 and von Willebrand factor (VWF), adjusted for three
sets of risk factors (I-III), with and without adjustment (+/)Adj.) for each other. Analyses are by thirds (ﬁrst third=1) and for a continuous increase of 1
standard deviation (SD). Only subjects with no missing values of any variables are included (n = 669).
Third
ADAMTS-13 VWF
)Adj. VWF +Adj. VWF )Adj. ADAMTS-13 +Adj. ADAMTS-13
Adjusted I
1 1 1 1 1
2 1.03 (0.71–1.50) 1.01 (0.69–1.48) 2.17 (1.48–3.17) 2.17 (1.49–3.18)
3 1.13 (0.78–1.64) 1.16 (0.79–1.71) 2.98 (2.02–4.38) 3.00 (2.04–4.42)
1 SD 1.01 (0.87–1.17) 1.03 (0.89–1.20) 1.50 (1.28–1.76) 1.51 (1.28–1.76)
Adjusted II
1 1 1 1 1
2 0.72 (0.45–1.16) 0.71 (0.44–1.15) 1.80 (1.11–2.91) 1.76 (1.08–2.86)
3 0.52 (0.31–0.85) 0.54 (0.32–0.89) 2.56 (1.58–4.16) 2.51 (1.54–4.09)
1 SD 0.72 (0.58–0.88) 0.73 (0.59–0.90) 1.42 (1.18–1.71) 1.40 (1.16–1.68)
Adjusted III
1 1 1 1 1
2 0.76 (0.47–1.23) 0.74 (0.45–1.20) 1.69 (1.04–2.75) 1.66 (1.01–2.71)
3 0.51 (0.31–0.85) 0.53 (0.32–0.88) 2.33 (1.42–3.83) 2.28 (1.38–3.75)
1 SD 0.72 (0.58–0.88) 0.73 (0.59–0.90) 1.37 (1.13–1.66) 1.35 (1.11–1.63)
Adjusted I: age and sex. Adjusted II: age, sex, systolic blood pressure (BP), diastolic BP, total serum cholesterol, high-density lipoprotein (HDL)-
cholesterol, triglycerides, diabetes, smoking (current/ex-/never), body mass index (BMI), use of medications for high BP and high cholesterol.
Adjusted III: age, sex, systolic BP, diastolic BP, total serum cholesterol, HDL-cholesterol, triglycerides, diabetes, smoking (current/ex-/never),
BMI, use of medications for high BP and high cholesterol, ﬁbrinogen and C-reactive protein.
Notes: The tertiles for ADAMTS-13 are 95.8 and 117.7% and for VWF are 144 and 195I U dL)1. One SD is given (for controls) in Table 1.
Table 3 Age- and sex-adjusted relationships between ADAMTS-13,
VWF and continuous coronary risk factors amongst controls. General
linear models were ﬁtted with transformed VWF or ADAMTS-13 as
dependent variables (transformations as in Table 1). Beta coeﬃcients




Age* )0.019 (P = 0.04) 0.010 (P < 0.0001)
Systolic BP 0.0003 (P = 0.94) 0.0003 (P = 0.76)
Diastolic BP 0.006 (P = 0.32) )0.001 (P = 0.36)
Total cholesterol 0.205 (P = 0.0005) 0.017 (P = 0.28)
HDL-cholesterol )0.678 (P < 0.0001) )0.016 (P = 0.71)
Triglycerides 0.021 (P = 0.03) 0.009 (P = 0.22)
BMI 0.077 (P < 0.0001) 0.004 (P = 0.30)
Fibrinogen 0.181 (P = 0.12) 0.107 (P = 0.0004)
CRP 0.005 (P = 0.57) 0.004 (P = 0.10)
BMI, body mass index; BP, blood pressure; CRP, C-reactive protein;
HDL-cholesterol, high-density lipoprotein-cholesterol. *Adjusted for
sex.
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inverse relationship between VWF and ADAMTS-13 [16];
however, these data revealed a moderate inverse correlation in
a small number of individuals and reported a more marked
effect following acute release of VWF. In that study ADAM-
TS-13 activity assays were used tomeasureADAMTS-13 levels
[16]. It remains uncertain how VWF levels in the plasma
samples may or may not have inﬂuenced the activity data
obtained. Although the study found an inverse relationship
between plasma VWF and ADAMTS-13 activity levels
measured following the acute-phase response to desmopressin,
the temporal changes in ADAMTS-13 and VWF levels are
open to several explanations. It may be beneﬁcial to measure
both ADAMTS-13 antigen and activity levels in order to more
accurately assess patient samples in future studies. Unfortu-
nately, determining ADAMTS-13 activity in the plasma
samples analyzed herein was not possible as the plasmas were
anticoagulated with EDTA, which precludes functional anal-
ysis of ADAMTS-13. That aside, accurate determination of
ADAMTS-13 activity data can be impractical for large patient
populations due to the difﬁculties/variability and costs associ-
ated with such assays.
The important ﬁnding that distinguishes the present study
fromourprevious case–control study is that in that study [14]we
found an unexpected increase in risk of MI with increasing
ADAMTS-13, whereas the present study found a decrease in
risk, albeit only after adjusting forCHDrisk factors,whichwere
not reported in theearlier study [14].Theearlier studycomprised
only male MI patients and controls, whereas the present study
investigated both men and women; however, even when we
restricted our analysis tomales, the results were almost identical
(data not shown), suggesting that this was not the cause of the
conﬂicting data. There were differences in the age ranges of the
two study populations but controlling for age did not appear to
alter the ﬁndings of the two studies (not shown).
Of the risk factors that we adjusted for, by far the most
important in masking the true association between ADAMTS-
13 andMIwasHDL-cholesterol. Future studies of ADAMTS-
13 may therefore need to take account of lipids, including
HDL-cholesterol, when assessing its association with MI.
However, at this time there is no mechanistic/biochemical data
that might explain this observed association. It must also be
considered that in epidemiology it is unusual to ﬁnd a
confounding effect where one variables effect only appears
after adjustment for another. Most often, adjustment attenu-
ates an effect. The unusual situation here is that the indepen-
dent effects of HDL-cholesterol and ADAMTS-13 both act in
the same (negative) direction on the risk of MI, yet the two
variables are negatively correlated with each other. Our results
suggest that it may be interesting to investigate the effect of
plasma lipids on ADAMTS-13.
The data from our present study in part agree with two
separate studies from the same group of investigators who
recently found that an increase in the VWF:ADAMTS-13 ratio
was associated with subsequent cardiovascular events in hospi-
tal post-MI in a small number of patients [17,18]. However, it
mustbeconsidered that,unlike inourcase–control studies, these
data analyzed VWF and ADAMTS-13 at time of admission to
hospital (and in one study over the subsequent 14 days), rather
than after the end of the acute-phase response. This is an
important consideration when comparing these data sets.
The present case–control study has the disadvantage of using
a study design that is relatively weak for estimating causality
[15]. In particular, survivor bias may have had some effect on
the results (cases had to be alive several months after their MI).
The lag time between the event and recruitment into the study,
for cases, was ideal for ensuring that transient inﬂammatory
changes, consequent to the event, had disappeared, but did
leave time for changes to lifestyle and treatment that will
usually occur after surviving a signiﬁcant medical event. This is
manifested here by the lower blood pressures in the case group,
the lack of difference between the cases and controls in average
cholesterol levels, and the same percentage (45%) of current
smokers amongst cases and controls at the time of surveying.
To deal with this problem, correlations and binary relation-
ships with ADAMTS-13 and VWF were analyzed separately
for cases and controls (although only the latter are presented);
medication use is included as an adjustment variable in the
analyses of association with MI; and smoking status is
dichotomized as ever or never smoked cigarettes. Another
limitation might be the poor general health of the north
Glasgow control group used here, reﬂected by the high
prevalence of smoking and taking blood pressure-lowering
treatment, and the suboptimal average values of risk factors
such as BMI. This might be expected to have led to an
underestimation of the effects of the associations between the
two novel risk factors considered here and MI.
We observed positive associations of VWF with ﬁbrinogen,
consistent with the known acute-phase reactant behavior of
VWF.We also observed negative associations of ADAMTS-13
with ﬁbrinogen and CRP, but only in cases (data not shown).
As in the previous study [14], there was little/no effect of
adjustment for ﬁbrinogen and CRP on the associations
between VWF or ADAMTS-13 and risk of MI.
In conclusion, we report that VWF and ADAMTS-13 levels
were not associated in this case–control study of MI; that
ADAMTS-13 levels were associated with blood lipid levels
(cholesterol, triglyceride, HDL-cholesterol) and obesity (BMI);
that VWF and ADAMTS-13 levels showed respectively
positive and negative associations with risk of MI; and that
the latter association was apparent only after adjustment for
CHD risk factors, in particular HDL-cholesterol. Further
studies, including adjustment for effects of blood lipids and
measurement of VWF multimers, are suggested in order to
clarify the relationships between ADAMTS-13, VWF and
cardiovascular risk.
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